A very similar CD28-CD3ζ CAR harboring the same FRP5-derived single-chain fragment variable antibody domain has been safely employed in phase I/II CAR-T clinical trials in pediatric patients with ErbB2+ sarcoma (41–43). This evidence concerns the gene CD28 and sarcoma.